Few careers in life sciences span the worlds of academic medicine, global pharmaceutical R&D, biotechnology and venture capital as extensively as that of Dr. Paul Peter Tak. From building a leading academic department in Amsterdam and becoming one of the Netherlands’ most prominent rheumatologists, to serving as Chief Immunology Officer at GlaxoSmithKline and later becoming President and CEO of Nasdaq-listed Candel Therapeutics, his career has been driven by a consistent ambition: to turn scientific knowledge into medicines that can make a meaningful difference for patients.